Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Arcellx, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Arcellx Provides First Quarter Financial Results REDWOOD CITY, Calif., May 8, 2023 /PRNewswire/ -- Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023. “Delivering our novel CAR-T therapy to multiple myeloma patients is at the heart of our mission,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “With the closing of our Kite partnership in the first quarter, we believe we are well capitalized to fund our operations through the first half of 2025. We remain laser-focused on key drivers of our business which include completing enrollment of iMMagine-1, i..." |
|
| 03/29/2023 |
8-K
| Quarterly results |
| 01/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/12/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results|
Docs:
|
"Arcellx Reports Third Quarter 2022 Financial Results and Business Progress -- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in December -- -- Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022, at 11:00 AM CT -- REDWOOD CITY, Calif., November 14, 2022 /PRNewswire/ -- Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the third quarter ended September 30, 2022. “Helping patient..." |
|
| 11/09/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Arcellx Appoints Olivia Ware to its Board of Directors — Replaces Lewis T. “Rusty” Williams, M.D. on Board of Directors — FOSTER CITY, Calif., May 16, 2022 /PRNewswire/ — Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointment of Olivia Ware to its Board of Directors. Ms. Ware, a successful executive, brings a wealth of knowledge from her more than 20 years of experience in biotech and pharmaceutical drug development, commercialization, and healthcare management. “On behalf of our entire Board, I'd like to thank Rusty for his many contributions to Arcellx as both a private and publicly traded biotech company. I've personally appreciated Rusty..." |
|
| 05/12/2022 |
8-K
| Quarterly results |
| 03/24/2022 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 24, 2022 Arcellx, Inc. Delaware 001-41259 47-2855917 25 West Watkins Mill Road, Suite A Gaithersburg, MD 20878 327-0603 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 ...",
"ARCELLX, INC. SELECTED CONSOLIDATED BALANCE SHEET DATA December 31, 2021 December 31, 2020 Cash, cash equivalents and marketable securities $ 104,617 $ 46,596 Total assets 128,782 57,694 Total liabilities 16,918 7,153 Redeemable convertible preferred stock 233,379 114,261 Total stockholders' deficit ARCELLX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended Year Ended December 31, December 31, 2021 2020 2021 2020 Revenue $ — $ — $ — $ — Operating expenses: Research and development 13,394 6,922 46,883 25,056 General and administrative 7,304 2,172 18,135 7,040 Total operating expenses 20,698 9,094 65,018 32,096 Loss from operations Other income, net 28 1 49 1 Net loss Other comprehensive loss: Unrealized loss on marketable securities 25 — 20 — Comprehe..." |
|
| 02/17/2022 |
8-K
| Entry into a Material Definitive Agreement |
| 02/09/2022 |
8-K
| Quarterly results |
|
|